Navigation Links
Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights
Date:8/7/2008

e, resulting in amortization of $0.8 million in the month of June 2008. On June 30, 2008, based upon a Black-Scholes valuation model that included a closing price of Genta's common stock of $0.38 per share, an additional expense of $380 million was recorded to mark the conversion feature liability to market, resulting in a total fair value conversion feature liability expense in June of $720.0 million and an expense of $7.2 million was recorded to mark the warrant liability to market.

Net other expense was $0.2 million for the second quarter of 2008 compared to net other income of $0.3 million for the second quarter of 2007, and net other expense was $0.1 million for the six months ended June 30, 2008 compared to net other income of $0.5 million. The difference resulted from lower investment income, owing to lower investment balances, and accrued interest on the convertible notes. The Company has no exposure to auction rate securities.

At June 30, 2008, Genta had cash, cash equivalents and marketable securities totaling $16.3 million compared with $7.8 million at December 31, 2007. During the first six months of 2008, cash used in operating activities was $14.4 million compared with $16.8 million for the same period in 2007, primarily as a result of the timing of payments in the two respective periods. The Company estimates that its average net cash outflow will be $2.0 to $2.5 million per month for the remainder of 2008.

Conference Call and Webcast

Genta management will host a conference call and live audio webcast to discuss these financial results and corporate activities on Thursday, August 7, 2008, at 8:00 am EDT. Participants can access the live call by dialing (877) 634-8606 (U.S. and Canada) or (706) 679-3140 (International). The access code for the live call is Genta Incorporated. The call will also be webcast live at http://www.genta.com/investorrelation/e
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Genta Announces Second Quarter 2008 Financial Results and Conference Call
2. Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane
3. Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia
4. Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs
5. Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights
6. Genta Announces Transfer of its Common Stock to the OTC Bulletin Board
7. Genta Announces Pending Transfer of its Common Stock to the Over-the-Counter Bulletin Board
8. Dr. Elizabeth Brown Joins Argenta TEC
9. Syngenta To Build Major Global Biotech Research Center in Beijing, China
10. Genta Restructures Operations to Focus on Priority Initiatives
11. Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... 3, 2015 ... osoitteessa  http://www.openinnovationinscience.at Wienissä pidettävään ... Science" -jatkokoulutusohjelmaan 22.7.2015 asti.  ... tekemän, kansainvälisiä tutkijoita ja tiedemiehiä ... suurinta haastetta ovat kannustimien puute ...
(Date:7/3/2015)... ... July 03, 2015 , ... The global failure analysis market is expected to ... The bioscience market is expected to grow at the highest CAGR of 8.46%; its ... in the research labs and academic institutions for root cause analysis of failure. The ...
(Date:7/3/2015)... 2015 Forskere kan ... in Science", som finner sted i ... nett, på  http://www.openinnovationinscience.at , og søknadsperioden varer ... De to største utfordringene innen helsevitenskapen er ... forskningsspørsmål og kompleksiteten av nåværende forskningsresultater, i ...
(Date:7/3/2015)... July 3, 2015 ... september 2015 på  http://www.openinnovationinscience.at om efteruddannelsesprogrammet ... finder sted i Wien ... af internationale forskere og videnskabsmænd foretaget af ... største udfordringer for sundhedsvidenskaben manglen på incitamenter ...
Breaking Biology Technology:Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 4Failure Analysis Market to Grow at 7.52% CAGR to 2020 5Lansering av verdens første Open Innovation-program for utdanning av forskere 2Lansering av verdens første Open Innovation-program for utdanning av forskere 3Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 3
... Reportlinker.com announces that a new market research report ... Biomarkers - Technologies,markets and companies ... follows the broad definition of a biomarker as ... evaluated as an indicator of normal biological or ...
... 2011 Reportlinker.com announces that a new ... catalogue: The 2011 Blood ... Opportunities and Business Expansion Strategies for Suppliers ... During the next ten years, the ...
... YORK, March 7, 2011 NeoStem, Inc. (NYSE Amex: ... operations in the U.S. and China, is pleased to ... Vice President of Strategic Business Development. Jason was formerly ... the firm,s research effort in emerging biotechnology companies. Jason,s ...
Cached Biology Technology:Reportlinker Adds Biomarkers - Technologies, Markets and Companies 2Reportlinker Adds The 2011 Blood Banking Market: US, Europe, Japan - Emerging Opportunities and Business Expansion Strategies for Suppliers 2NeoStem Announces the Addition of Jason Kolbert as Vice President of Strategic Business Development 2NeoStem Announces the Addition of Jason Kolbert as Vice President of Strategic Business Development 3
(Date:7/2/2015)... 2, 2015 Fingerprint Cards has received ... and FPC1155 from the distributor World Peace Industrial Group (WPI), ... in Asia . Deliveries are planned to ... be used by smartphone manufacturers in Asia ... the communicated revenue guidance of approximately 2,200 MSEK for 2015. ...
(Date:6/26/2015)... ATL Technology, LLC, a top provider of electromechanical contract manufacturing ... headquartered in Springville, Utah , has announced ... corporation with locations in Santa Clara, CA ... ). This acquisition will incorporate MedConx,s manufacturing facility ... existing facility in Costa Rica , resulting ...
(Date:6/24/2015)... , June 24, 2015 The biologics safety ... major drivers for the market include growth of the ... new drug launches. Over the years, the number of ... 2001 and 2010, the FDA approved 225 drug applications ... WIPO, Europe accounted for 3,822 ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... Netherlands,Thursday 25 April 2013: Probiotics could emerge as ... therapy after a new study announced at ... reduced development of the notoriously difficult-to-treat disease. ... preventing the development of HE in 160 cirrhotic ...
... Liver Congress 2013 include results from early in vitro ... (cccDNA), which may form the basis of a cure ... cccDNA is organized into mini-chromosomes within the nucleus of ... availability of efficient therapies against HBV, long-term persistence of ...
... 2013, a novel H7N9 influenza virus was identified in ... in humans, resulting in some deaths. A group of ... Reference Laboratory, State Key Laboratory of Veterinary Biotechnology, Harbin ... investigated the origins of this novel H7N9 influenza virus ...
Cached Biology News:Probiotics found to reduce hepatic encephalopathy 2Novel therapeutic approaches to cure chronic HBV infection 2Novel therapeutic approaches to cure chronic HBV infection 3Source identification of H7N9 influenza virus causing human infections 2Source identification of H7N9 influenza virus causing human infections 3
Duck polyclonal to Cobra venom - Fab Fragment ( Abpromise for all tested applications). Antigen: Snake Venom of N. naja arta...
Anti-human C5a/C5a des-Arg (neo-epitode), Clone 2952, Monoclonal Antibody...
...
Reacts with the 80 kDa fragment of the M-chain of human merosin....
Biology Products: